12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SB 9200: Phase I started

Spring Bank began a 2-part Australian Phase I trial to evaluate once-daily oral SB 9200 in treatment-naïve HCV genotype 1 patients. The first, open-label portion will evaluate single ascending-doses of 100-800 mg SB 9200 in 4...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >